menu
    • menu
    [{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I","graph3":"LaNova Medicines","amount2":0.22,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Turning Point Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"LaNova Medicines \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"LM-305","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"LaNova Medicines \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ AstraZeneca"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"LM-302","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"LaNova Medicines \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":3.29,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.29,"dosageForm":"","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"GI Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"GI-102","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ LaNova Medicines","highestDevelopmentStatusID":"4","companyTruncated":"LaNova Medicines \/ LaNova Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by LaNova Medicines

    Menu

    LaNova Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GI-102,LM-302

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : GI Innovation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GI Innovation-LaNova Signs MOU for GI-102 + ADC in Pancreatic Cancer Therapy

                            Details : Through this agreement, both companies will conduct clinical trial of GI-102 in combination with LM-302 targeting patients with metastatic pancreatic cancer.

                            Product Name : GI-102

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            January 22, 2025

                            Lead Product(s) : GI-102,LM-302

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : GI Innovation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-299

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $3,288.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck Licenses LM-299, An Anti-PD-1/VEGF Bispecific Antibody for Global Development

                            Details : The agreement aims to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.

                            Product Name : LM-299

                            Product Type : Large molecule

                            Upfront Cash : $588.0 million

                            December 20, 2024

                            Lead Product(s) : LM-299

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $3,288.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-299

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $3,288.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck Signs Up to $3.3 Billion Cancer Drug Deal with China-Based Lanova

                            Details : Merck will acquire the global rights to develop and market LM-299, a novel investigational PD-1/VEGF bispecific antibody, for the treatment of advanced solid tumours.

                            Product Name : LM-299

                            Product Type : Large molecule

                            Upfront Cash : $588.0 million

                            November 16, 2024

                            Lead Product(s) : LM-299

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $3,288.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-302,Rivoceranib,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sino Biopharmaceutical

                            Deal Size : $42.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            LaNova Initiates Phase 1 for LM-299 Anti-PD-1/VEGF Antibody and $42M Financing

                            Details : The financing is intended to support the clinical development of LM-302, an anti-CLDN 18.2 ADC, which is currently in late-stage clinical trials in China for the treatment of gastric cancers.

                            Product Name : LM-302

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2024

                            Lead Product(s) : LM-302,Rivoceranib,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sino Biopharmaceutical

                            Deal Size : $42.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LaNova Medicines

                            China arrow
                            The Generic Rx Session
                            Not Confirmed

                            LaNova Medicines

                            China arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-305,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : $600.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targ...

                            Details : Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5,...

                            Product Name : LM-305

                            Product Type : Large molecule

                            Upfront Cash : $55.0 million

                            May 12, 2023

                            Lead Product(s) : LM-305,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : $600.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            LaNova Medicines

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-302

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Turning Point Therapeutics

                            Deal Size : $220.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti...

                            Details : TPX-4589 (LM-302) is a potentially first-in-class anti-Claudin18.2 ADC discovered by LaNova that suppresses cell proliferation of gastric and pancreatic cell lines with nanomolar potency in preclinical models. It also has demonstrated efficacy in gastric...

                            Product Name : TPX-4589

                            Product Type : Large molecule

                            Upfront Cash : $25.0 million

                            May 05, 2022

                            Lead Product(s) : LM-302

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Turning Point Therapeutics

                            Deal Size : $220.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth